What is Goserelin?

A GnRH analog implant (Zoladex) used to lower sex-hormone levels in prostate and breast cancer and gynecologic conditions.

Goserelin in the library · · Human Trials · What are peptides?

308 registered trials · 571 indexed papers · 578 human / 2 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A GnRH analog implant (Zoladex) used to lower sex-hormone levels in prostate and breast cancer and gynecologic conditions.

Type: GnRH analog peptide.

Definition (National Library of Medicine)

“A synthetic long-acting agonist of gonadotropin-releasing hormone.”

  • MeSH: Goserelin

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Goserelin is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (308)

TrialPhaseStatusYearEnrolled
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerPhase 3recruiting20261500
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX [amount hidden] in Premenopausal Women With Early-stage and Advanced HR+ Breast CancerPhase 1recruiting2026176
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerPhase 2recruiting2026600
Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer PatientsPhase 2recruiting202698
Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast CancerPhase 2not yet recruiting202636
QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyPhase 2not yet recruiting202640
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire DisorderPhase 1/Phase 2not yet recruiting2026100
ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)Phase 3not yet recruiting2026600
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialPhase 2recruiting202675
Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelinnot yet recruiting202664
Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using Goserelinnot yet recruiting202664
Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelinnot yet recruiting2026132
The COSMYC Trial (COmbined Suppression of MYC)Phase 2recruiting202550
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine TherapyPhase 2recruiting2025140
A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male ParticipantsPhase 1completed202555
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryPhase 2recruiting202574
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate CancerPhase 2withdrawn2025
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyPhase 2not yet recruiting2025288
Phase IIIb Study of Ribociclib + ET in Early Breast CancerPhase 3recruiting20241444
Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)Phase 2recruiting202430
Adaptions and Resiliency to Multi-Stressor OpeRationsPhase 4recruiting2024120
First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast CancerPhase 2completed202474
Effect of a GnRH Analog on Hepatic SteatosisPhase 4active not recruiting202462
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialPhase 2recruiting2024532
Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancercompleted202414
Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer PatientsPhase 2recruiting2024124
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate CancerPhase 2recruiting202480
To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate CancerPhase 2unknown202460
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)Phase 2recruiting202440
Neo-DAB: Darolutamide and Abemaciclib in Prostate CancerPhase 1terminated20239
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerPhase 1active not recruiting202328
Contributions to Hypertension With Androgen Deprivation TherapyPhase 4terminated202310
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene AlterationsPhase 2active not recruiting202332
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast CancerPhase 2active not recruiting202387
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingPhase 2recruiting202339
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersPhase 2/Phase 3recruiting2023493
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finlandcompleted20231083
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerPhase 2recruiting202350
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCPhase 2recruiting202342
Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624Phase 3recruiting2023534

Peer-reviewed studies (571)

PaperAuthorsJournalYearType
Impact of leuprolide and goserelin on androgen suppression and adverse events in patients with prostate cancerFreitas CSM et al.The Canadian journal of urology2026Randomized Controlled Trial
Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY TrialOkano S et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2026Clinical Trial, Phase II
Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II studyEngebrethsen C et al.Breast (Edinburgh, Scotland)2026Clinical Trial, Phase II
Prospective study of endogenous testosterone recovery following neoadjuvant hormonal blockade and radical prostatectomy in high-risk prostate cancer patientsNascimento BCG et al.The journal of sexual medicine2025Randomized Controlled Trial
A Non-Inferior Randomized Trial of Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Premenopausal Patients With Hormone-Responsive and HER2-Negative Lymph Node-Negative Breast CancerGu C et al.Cancer control : journal of the Moffitt Cancer Center2025Randomized Controlled Trial
[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex(®) for patients with premenopausal breast cancer]Shao XY et al.Zhonghua zhong liu za zhi [Chinese journal of oncology]2025Randomized Controlled Trial
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trialHortobagyi GN et al.Annals of oncology : official journal of the European Society for Medical Oncology2025Randomized Controlled Trial
Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical TrialAh-Thiane L et al.European urology oncology2025Clinical Trial, Phase II
Multicenter, prospective, single-arm clinical study to investigate the efficacy and safety of Zoladex (Goserelin acetate) [amount hidden] prior to surgery in Chinese premenopausal women with symptomatic uterine fibroidsLiang Y et al.Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology2024Clinical Trial
Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trialCardili L et al.World journal of urology2024Randomized Controlled Trial
Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized studyShao Z et al.Cancer medicine2024Randomized Controlled Trial
Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASUHonma Y et al.Clinical cancer research : an official journal of the American Association for Cancer Research2024Clinical Trial, Phase II
Ribociclib plus Endocrine Therapy in Early Breast CancerSlamon D et al.The New England journal of medicine2024Randomized Controlled Trial
Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancerChen N et al.Cancer biology & medicine2024Observational Study
Clinical analysis of acute postoperative pain after total laparoscopic hysterectomy for adenomyosis and uterine fibroids - a prospective observational studyWu Q et al.Annals of medicine2023Observational Study
A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapyTaguchi S et al.Japanese journal of clinical oncology2023Observational Study
Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trialGu C et al.Chinese medical journal2023Clinical Trial, Phase III
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical TrialJohansson A et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2022Randomized Controlled Trial
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trialZapatero A et al.The Lancet. Oncology2022Randomized Controlled Trial
Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapySasaki H et al.Andrology2022Randomized Controlled Trial
Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancerRyu HH et al.Scientific reports2021Randomized Controlled Trial
The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trialR L et al.Breast (Edinburgh, Scotland)2020Randomized Controlled Trial
Dose-Response Relationships Between Gonadal Steroids and Bone, Body Composition, and Sexual Function in Aging MenFinkelstein JS et al.The Journal of clinical endocrinology and metabolism2020Randomized Controlled Trial
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancerKim HJ et al.Breast cancer research : BCR2020Randomized Controlled Trial
Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapyHawley JE et al.The Prostate2020Randomized Controlled Trial
The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levelsWerutsky G et al.BMC cancer2019Randomized Controlled Trial
Genome-wide gene expression in a pharmacological hormonal transition model and its relation to depressive symptomsMehta D et al.Acta psychiatrica Scandinavica2019Randomized Controlled Trial
Effect of Testosterone on Natriuretic Peptide LevelsBachmann KN et al.Journal of the American College of Cardiology2019Randomized Controlled Trial
Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapyDeka R et al.Cancer2019Observational Study
Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatmentCampbell AM et al.BMJ open2018Clinical Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Goserelin?

A GnRH analog implant (Zoladex) used to lower sex-hormone levels in prostate and breast cancer and gynecologic conditions.

How many registered human trials study Goserelin?

The PeptideWhiz trial index lists 308 registered trials for Goserelin, the most recent from 2026.

How much published research exists on Goserelin?

The PeptideWhiz paper index links 571 PubMed papers to Goserelin; by study type, 578 human and 2 animal studies.

Which conditions is Goserelin researched for?

Anemia, Anti-aging & longevity, Atherosclerosis, cardiovascular disease & high blood pressure, Cognition, focus & brain performance, Endometriosis, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Female fertility, High cholesterol and statins, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Low testosterone (without or alongside TRT), Male fertility and sperm, Menopause & perimenopause, Migraine, Muscle gain, sarcopenia & building muscle after 40, Osteoporosis and bone density, PCOS, PMDD (premenstrual dysphoric disorder), Post-surgical inflammation and surgery recovery, Pregnancy and breastfeeding: safety notes, Prostate inflammation, Sexual function & libido (women and men).

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research